Skip to main content
. 2019 Nov 13;9(1):151–159. doi: 10.1002/cam4.2693

Figure 4.

Figure 4

Percentages of patients in the GM1/placebo arm continuing to use (A) full doses of oxaliplatin over time (P = .08) or (B) oxaliplatin over time (P = .26). C, Mean doses of oxaliplatin in the GM1/placebo arms over time (P = .39). GM1, monosialotetrahexosylganglioside